|
C4ORF48 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
4.790100E-04 |
| Normal-vs-Stage3 |
2.12996287274336E-12 |
| Normal-vs-Stage4 |
6.59699994631779E-09 |
| Stage1-vs-Stage2 |
4.785200E-01 |
| Stage1-vs-Stage3 |
3.302600E-01 |
| Stage1-vs-Stage4 |
4.990800E-01 |
| Stage2-vs-Stage3 |
2.804800E-01 |
| Stage2-vs-Stage4 |
3.256200E-01 |
| Stage3-vs-Stage4 |
8.848000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.26539999998998E-05 |
| Normal-vs-Asian |
4.07129999713263E-08 |
| Caucasian-vs-AfricanAmerican |
6.972600E-01 |
| Caucasian-vs-Asian |
9.159600E-01 |
| AfricanAmerican-vs-Asian |
7.031000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.57930385120176E-11 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.523000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68187686000465E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.0810999873101E-09 |
| Normal-vs-Age(81-100Yrs) |
3.356500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.233900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.607800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.009900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.469000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.827600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.407800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.871200E-01 |
| Classical-VS-Follicular |
7.648300E-02 |
| Classical-VS-Other |
6.135400E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
4.935900E-02 |
| Tall-VS-Other |
3.153400E-01 |
| Tall-VS-Normal |
1.197040E-03 |
| Follicular-VS-Other |
9.085400E-01 |
| Follicular-VS-Normal |
7.7111000029717E-08 |
| Other-VS-Normal |
8.903700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62458935193399E-12 |
| Normal-vs-N1 |
5.90049997750697E-09 |
| N0-vs-N1 |
1.450210E-01 |
|
|
